Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.

[1]  Alexandre Mamedov,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[3]  Stacey A. Kenfield,et al.  Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Peter C Albertsen,et al.  Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. , 2009, Journal of the National Cancer Institute.

[5]  Harry J de Koning,et al.  Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). , 2009, European urology.

[6]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[7]  Alan Horwich,et al.  Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. , 2008, European urology.

[8]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[9]  Steve Williams,et al.  Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience , 2007, BJU international.

[10]  E. Metter,et al.  Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience , 2007 .

[11]  D. Lin.  Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: Characteristics, PSA doubling times, and outcome , 2007 .

[12]  J. Hugosson,et al.  Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174)) , 2007 .

[13]  Matthew R Cooperberg,et al.  Contemporary trends in low risk prostate cancer: risk assessment and treatment. , 2007, The Journal of urology.

[14]  Liying Zhang,et al.  Modeling prostate specific antigen kinetics in patients on active surveillance. , 2006, The Journal of urology.

[15]  L. Collette,et al.  Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Ali,et al.  PSA doubling time predicts the outcome after active surveillance in screening‐detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section , 2006 .

[17]  M. Cooperberg,et al.  The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. , 2004, The Journal of urology.

[18]  Hongyu Wu,et al.  Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Greene.  AJCC cancer staging handbook , 2002 .

[20]  L Souhami,et al.  Controversies in prostate cancer radiotherapy: consensus development. , 2001, The Canadian journal of urology.

[21]  A. Renshaw,et al.  Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Kirkpatrick.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. , 1998, Journal of insurance medicine.